David Bianculli

Celgene still had a monopoly on the marketplace, and they maintained that monopoly until 2022. In 2015, they settled with one of the generic companies who was involved in litigation with them. And that settlement required the generic maker to stay out of the marketplace until 2022. And even when it comes into the marketplace in a very limited way, less than 10% of the market.

Celgene still had a monopoly on the marketplace, and they maintained that monopoly until 2022. In 2015, they settled with one of the generic companies who was involved in litigation with them. And that settlement required the generic maker to stay out of the marketplace until 2022. And even when it comes into the marketplace in a very limited way, less than 10% of the market.

Celgene still had a monopoly on the marketplace, and they maintained that monopoly until 2022. In 2015, they settled with one of the generic companies who was involved in litigation with them. And that settlement required the generic maker to stay out of the marketplace until 2022. And even when it comes into the marketplace in a very limited way, less than 10% of the market.

2026.

2026.

2026.

What we found is the company in certain situations used Revlimid to boost overall revenues. There was a situation in 2014 where Revlimid sales were not up to what the company expected. And a memo was sent out saying we need a price increase. Another situation in 2017 where they had a

What we found is the company in certain situations used Revlimid to boost overall revenues. There was a situation in 2014 where Revlimid sales were not up to what the company expected. And a memo was sent out saying we need a price increase. Another situation in 2017 where they had a

What we found is the company in certain situations used Revlimid to boost overall revenues. There was a situation in 2014 where Revlimid sales were not up to what the company expected. And a memo was sent out saying we need a price increase. Another situation in 2017 where they had a

a drug that was very promising for another condition called Crohn's disease, failed and they abandoned that project. And the day they abandoned that project, they raised the price of Revlimid 9%. You know, we've described it essentially as a piggy bank. They could tap Revlimid whenever they needed to. And there was really no regulator or governor on the price increases.

a drug that was very promising for another condition called Crohn's disease, failed and they abandoned that project. And the day they abandoned that project, they raised the price of Revlimid 9%. You know, we've described it essentially as a piggy bank. They could tap Revlimid whenever they needed to. And there was really no regulator or governor on the price increases.

a drug that was very promising for another condition called Crohn's disease, failed and they abandoned that project. And the day they abandoned that project, they raised the price of Revlimid 9%. You know, we've described it essentially as a piggy bank. They could tap Revlimid whenever they needed to. And there was really no regulator or governor on the price increases.

It was really up to the company.

It was really up to the company.

It was really up to the company.

We did. In 2017, they raised the price 20% during the year. And one of the company officials filed a whistleblower complaint. And in her complaint, she said she was at a meeting and she objected to these price increases. She said it was just too much. And she said the CEO admonished her, said, what's the worst that's going to happen, a bad tweet?

We did. In 2017, they raised the price 20% during the year. And one of the company officials filed a whistleblower complaint. And in her complaint, she said she was at a meeting and she objected to these price increases. She said it was just too much. And she said the CEO admonished her, said, what's the worst that's going to happen, a bad tweet?

We did. In 2017, they raised the price 20% during the year. And one of the company officials filed a whistleblower complaint. And in her complaint, she said she was at a meeting and she objected to these price increases. She said it was just too much. And she said the CEO admonished her, said, what's the worst that's going to happen, a bad tweet?

And that's how she said they viewed these price increases.

And that's how she said they viewed these price increases.